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doi:10.1Objective: Cyclooxygenase-2 inhibitors have been implicated in adverse cardiac events. We hypothesize that
hypercholesterolemia and ischemia may alter the myocardial response to the cyclooxygenase-2 inhibitor
celecoxib.
Methods:Yorkshire swine fed normal chow (CX, n¼ 6) or high-cholesterol diet (HCX, n¼ 6) underwent place-
ment of an Ameroid constrictor on the left circumflex artery and were started on celecoxib (200 mg/day). After 7
weeks, ischemic and nonischemic myocardium was analyzed for thrombogenic ratio (thromboxane content di-
vided by prostacyclin content), total protein oxidative stress, and expression of prostacyclin synthase, thrombox-
ane synthase, myeloperoxidase, and superoxide dismutase. Cardiac function, tissue perfusion, and vessel density
were measured.
Results: HCX animals were significantly hypercholesterolemic compared with CX animals. Thrombogenic ra-
tio was significantly higher in the HCX group than in the CX group, but prostacyclin and thromboxane synthase
expression was similar in all tissues. Myocardial perfusion was decreased in the HCX group compared with the
CX group. Total oxidative stress, myeloperoxidase, and superoxide dismutase were increased in ischemic tissue
compared with nonischemic tissues, but there was no diet-induced difference between groups. There was no dif-
ference in capillary or arteriolar density between groups. Left ventricular contractility was greater in the HCX
group than in the CX group, but there was no significant difference in heart rate, mean arterial pressure, or left
ventricular pressure.
Conclusions: Hypercholesterolemic patients using celecoxib may be at higher risk for thrombotic events than
those with normal cholesterol, but the relationship between dyslipidemia, ischemia, and cyclooxygenase-2
inhibition is likelymuchmore complicated than originally thought. (J Thorac Cardiovasc Surg 2011;142:675-81)Nonsteroidal anti-inflammatory drugs inhibit the conversion
of arachidonic acid into prostaglandin H2 by cyclooxyge-
nase (COX), decreasing downstream synthesis of prosta-
glandins, which are responsible for the symptoms of pain,
inflammation, and fever. COX also converts arachidonic
acid into prostacyclin, a vasodilator and inhibitor of platelet
aggregation, and thromboxane, a vasoconstrictor and pro-
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Smaintain gastric mucosa and decreases gastric acid produc-
tion. Thus, the use of traditional COX inhibitors has been
limited by increased risk of gastrointestinal complications.
In 1991, COX-2 was discovered, which was found to be
induced only at sites of inflammation.1 Subsequently, COX-
2–specific inhibitors were developed to target the undesir-
able effects of prostaglandins while sparing the protective
physiologic effects. Unfortunately, although they did de-
crease the incidence of gastrointestinal complications,
several of these medications were found to increase cardio-
vascular risk compared with placebo and nonselective COX
inhibitors, leading to their withdrawal fromworldwide mar-
kets.2 The majority of these studies, however, did not assess
the effect of comorbidities such as hypercholesterolemia or
chronic ischemia on the safety profile of COX-2 inhibitors.
The COX-2 inhibitors parecoxib and valdecoxib have been
found to increase cardiovascular and other major complica-
tions compared with placebo after coronary artery bypass
surgery3,4 but not after noncardiac surgery,5 suggesting
that cardiovascular comorbidities indeed affect the response
to COX-2 inhibition. Unfortunately, the swiftness with
which COX-2 inhibitors were removed from the market
has made more directed clinical evaluation of their safety
difficult.rdiovascular Surgery c Volume 142, Number 3 675
Abbreviations and Acronyms
AAR ¼ area at risk
CX ¼ normal chow
COX ¼ cyclooxygenase
HCX ¼ high cholesterol diet
HDL ¼ high-density lipid (cholesterol)
LDL ¼ low-density lipid (cholesterol)
LV ¼ left ventricular
NV ¼ nonischemic left ventricular tissue
SDS-
PAGE
¼ sodium dodecylsulfate–
polyacrylamide gel electrophoresis
SOD ¼ superoxide dismutase
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SCelecoxib is reported to have the most benign safety pro-
file of all of the COX-2 inhibitors,6 perhaps related to its
unique ability to improve endothelial function and smooth
muscle relaxation in the setting of coronary artery disease.7
On the other hand, it has also been reported to increase vas-
cular oxidative stress8 and to have antiangiogenic effects.9
We recently found that celecoxib improved blood flow in
the ischemic myocardium of hypercholesterolemic pigs
compared with untreated animals (Chu et al, submitted to
Am J Physiol, 2011), an effect that was not seen in normo-
cholesterolemic swine.9 Thus, cardiovascular comorbidities
clearly influence the myocardial response to selective
COX-2 inhibition with celecoxib. We designed this study
to examine the effects of ischemia and hypercholesterol-
emia in the setting of celecoxib treatment.
MATERIALS AND METHODS
Study Design
Yorkshire miniswine (Parsons Research, Amherst, Mass) were fed ei-
ther normal chow (CX, n ¼ 6) or high cholesterol diet (Sinclair Research,
Columbia,Mo) (HCX, n¼ 6). At 8 weeks of age, animals underwent place-
ment of an Ameroid constrictor (Research Instruments SW, Escondido,
Calif) on the left circumflex coronary artery . All animals were then started
on oral celecoxib (200 mg once daily).
Seven weeks later, coronary angiography was performed. The heart was
then exposed via midline sternotomy and physiologic measurements were
taken, followed by blood draw and cardiac harvest. Nonischemic left ven-
tricular (LV) tissue (NV) was harvested from directly adjacent to the left
anterior descending coronary artery, while myocardium from the ischemic
area at risk (AAR) was harvested from the left circumflex territory. Tissue
samples were flash frozen in liquid nitrogen for subsequent analysis.
All experiments were approved by the Beth Israel Deaconess Medical
Center and Rhode Island Hospital Institutional Animal Care and Use com-
mittees. Animals were cared for in accordance with the ‘‘Principles of Lab-
oratory Animal Care’’ formulated by the National Society for Medical
Research and the ‘‘Guide for the Care and Use of Laboratory Animals’’
(NIH publication No. 5377-3, 1996).
Serum Lipid Profile
Pig serum was analyzed for total cholesterol, high-density lipid (HDL)
cholesterol, and triglycerides using a Beckman DXC 800 Chemistry Ana-
lyzer (Beckman Coulter Inc, Brea, Calif). Low-density lipid (LDL)676 The Journal of Thoracic and Cardiovascular Surgcholesterol was calculated from these results using the formula:
LDL ¼ total cholesterol – HDL – (triglycerides/5).
Measurement of Global Myocardial Function
Heart rate, mean arterial pressure, developed LV pressure, and LV con-
tractility were recorded before cardiac harvest using single-sensor pressure
catheters (Millar Instruments, Inc, Houston, Tex) introduced through the
apex of the heart and into the abdominal aorta via a femoral artery sheath.
Myocardial Perfusion Analysis
Myocardial perfusion was measured via isotope-labeled microspheres
(BioPAL, Worcester, Mass). Gold-labeled microspheres were injected dur-
ing temporary occlusion of the left circumflex artery at the first procedure
to demarcate the AAR. Microspheres labeled with lutetium (resting heart
rate) and europium (pacing to 150 beats/min) were injected at the final pro-
cedure while blood was simultaneously withdrawn from the femoral artery
catheter. Dried LV samples were exposed to neutron beams and micro-
sphere densities measured using a gamma counter (BioPAL). Myocardial
blood flow was determined using the following equation:
Blood flow ¼ ðwithdrawal rate=tissue weightÞ3
ðtissue microsphere count=blood microsphere countÞ
Thrombogenic Ratio
Tissue levels of the breakdown products of thromboxane A2 and prosta-
cyclin, 11-dehydrothromboxane-B2 and 6-keto prostaglandin-F1a, respec-
tively, were measured using enzyme-linked immunosorbent assay kits
(Neogen Corp, Lexington, Ky). Tissue lysates underwent liquid–liquid ex-
change, extraction, and concentration, and were then loaded into 96-well
plates containing antibody to either 11-dehydrothromboxane-B2 or 6-keto
prostaglandin-F1a. After addition of colorimetric substrate, absorbance
was read at 650 nm. Results were expressed as a ‘‘thrombogenic ratio’’ or
the ratio of 11-dehydrothromboxane-B2 to 6-keto prostaglandin-F1a.
Immunoblotting
Sixtymicrogramsof total protein frommyocardial homogenateswas frac-
tionated by sodium dodecylsulfate–polyacrylamide gel electrophoresis
(SDS-PAGE; Invitrogen, San Diego, Calif) and transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, Mass). Membranes were incu-
bated with antibodies against prostacyclin synthase, thromboxane synthase
(Cayman Chemical, Ann Arbor, Mich), myeloperoxidase (Sigma-Aldrich,
St Louis, Mo), Cu/Zn-superoxide dismutase (Cu/Zn-SOD), and Mn-
superoxide dismutase (Mn-SOD; Enzo Life Sciences, Plymouth Meeting,
Pa) at dilutions recommended by themanufacturer, followed by the appropri-
ate horseradish peroxidase–linked secondary antibodies (1:3000; Jackson
ImmunoResearch, West Grove, Pa). Bands were visualized via chemilumi-
nescence (Amersham, Piscataway, NJ) and photographed using GeneSnap
software (Syngene, Cambridge, England). Densitometry was performed us-
ing Image J software (National Institutes of Health, Bethesda, Md). Ponceau
staining was used to ensure equal protein loading.
Total protein oxidative stress was measured using the Oxyblot kit (Milli-
pore, Billerica, Mass). Dinitrophenylhydrazine-derivatized tissue homoge-
nates from the AAR were separated by SDS-PAGE and transferred to
polyvinylidene difluoride membranes. Membranes were incubated with
primary antibody to dinitrophenylhydrazine, followed by horseradish per-
oxidase–linked secondary antibody per manufacterer’s recommendations.
Immune complexes were visualized with chemiluminescence, and densi-
tometry was applied to entire lanes to measure total protein oxidation.
Immunohistochemical Staining for Capillary and
Arteriolar Density
Frozen myocardial sections, 12-mm thick, were formalin fixed and then
incubated with antibody against porcine CD31 (1:200; R&D Systems,ery c September 2011
FIGURE 1. Hemodynamic parameters. Heart rate (HR), mean arterial pressure (MAP), developed left ventricular pressure (dLVP), and LV contractility
(dP/dt) were measured at the time of cardiac harvest. There was no significant difference in HR (A), MAP (B), or dLVP (C) between groups, though
MAP tended to be lower in the HCX group. The dLVP was significantly increased in the HCX group (D). CX, Normal chow; HCX, high cholesterol diet.
Chu et al Evolving Technology/Basic ScienceMinneapolis, Minn) and smooth muscle actin (1:400; Sigma-Aldrich), fol-
lowed by approriate DyLight-conjugated secondary antibodies (1:100;
Jackson ImmunoResearch, West Grove, Pa). Sections were mounted in
Vectashield with 40,6-diamidino-2-phenylindole (Vector Laboratories,
Burlingame, Calif). Three randomly selected photomicrographs were taken
of each section with a Zeiss Axiolab microscope (Carl Zeiss, Inc, Thorn-
wood, NY) at 203 magnification. Capillaries, defined as CD31-positive
structures between 5 and 25 mm2 in cross-sectional area, were counted us-
ing Image J software for each micrograph and averaged for each section.
Arterioles were defined as structures that stained positively for both smooth
muscle actin and CD31 and counted in a similar fashion. Data are presented
as vessels per square millimeter.
Statistical Analysis
Results are presented as mean  standard error of the mean. Statistical
comparisons were carried out with GraphPad Prism 5.0 Software (Graph-
Pad Software Inc, SanDiego, Calif) using a 2-way analysis of variance. The
Newman-Keuls multiple comparison test was applied to test for signifi-
cance between groups.E
T
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SRESULTS
Animal Model
Of 7 animals originally included per group, 1 from each
group died before cardiac harvest, presumably from cardiac
arrhythmia, for a total 6 per group. All animals demon-
strated complete occlusion of the left circumflex coronary
artery at the time of cardiac harvest. Serum cholesterol
values were significantly elevated in the HCX groupThe Journal of Thoracic and Ca(243.9  21.7 mg/dL vs 78.7  3.7 mg/dL; P< .0001).
HDL cholesterol was also increased in the HCX group
(60.5  8.4 mg/dL vs 27.8  2.32 mg/dL; P<.01). How-
ever, the ratio of HDL/LDL cholesterol was significantly
decreased in the HCX group compared with the CX group
(0.40  0.04 mg/dL vs 0.66  0.07 mg/dL; P<.01).
LVcontractilitywas significantly higher in theHCXgroup
than in theCXgroup, but therewas no difference in heart rate
or LV pressure. There was a strong trend toward decreased
mean arterial pressure in the HCX group, but this difference
did not reach statistical significance (Figure 1, A–D).
Myocardial perfusion. Resting myocardial perfusion was
significantly lower in the NVof hypercholesterolemic swine
compared with normocholesterolemic swine and tended to
be lower in the AAR as well. Overall, there was a significant
effect of hypercholesterolemia in reducing myocardial per-
fusion at rest. Perfusion was similar between the AAR and
the NV of both normal and hypercholesterolemic swine
(Figure 2, A).
Similarly, there was a significant decrease in paced blood
flow in the NVof hyperchoelsterolemic swine, but overall,
hypercholesterolemia did not have a significant effect on
paced blood flow (Figure 2, B).
Thrombogenic ratio. Thrombogenic ratio was signifi-
cantly increased in the NV and AAR of hypercholesterol-
emic swine compared with normal diet swine. Therdiovascular Surgery c Volume 142, Number 3 677
FIGURE 2. Myocardial blood flow. Blood flow in ischemic and nonischemic myocardium from both groups was measured by microsphere analysis. Under
resting conditions (A), blood flowwas significantly decreased in the NVof HCX swine compared with CX swine, and therewas a significant overall effect of
hypercholesterolemia in decreasing perfusion as well. Under ventricular pacing (B), blood flowwas again decreased in the NVof HCX swine compared with
CX swine, but there was no overall effect of hypercholesterolemic diet. CX, Normal chow; HCX, high cholesterol diet; NV, nonischemic left ventricular
tissue; AAR, area at risk. *P<.05.
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Sthrombogenic ratio was also lower in the AAR of normo-
cholesterolemic animals compared with the NV. The same
trend was seen in hypercholesterolemic animals, although
this difference was not significant (Figure 3).
Protein expression. There was no difference in the expres-
sion of prostacyclin synthase or thromboxane synthase
between groups or myocardial territories. Expression of
myeloperoxidase, Mn-SOD, and Cu/Zn-SOD were in-
creased in ischemic tissue compared with nonischemicFIGURE 3. Thrombogenic ratio. Tissue levels of the stable metabolites of
thromboxane and prostacyclin were measured and expressed as a ratio of
11-dehydrothromboxane-B2 to 6-keto-prostaglandin F1a. Thrombogenic
ratio was increased in the HCX group, but it tended to be decreased in
ischemic myocardium. CX, Normal chow; HCX, high cholesterol diet;
NV, nonischemic left ventricular tissue; AAR, area at risk. *P<.05.
678 The Journal of Thoracic and Cardiovascular Surgtissues, but there was no diet-induced difference in expres-
sion (Figure 4, A to E).
Protein oxidative stress. Total protein oxidative stress was
increased in the ischemic territories of both groups, whereas
hypercholesterolemia had no significant effect on protein
oxidation (Figure 4, F).
Vessel density. Neither capillary nor arteriolar density was
significantly different between groups or myocardial terri-
tories, although arteriolar density did tend to be somewhat
decreased in HCX animals (Figure 5).
DISCUSSION
Many previous studies have evaluated the effects of cele-
coxib on angiogenesis, thrombogenesis, oxidative stress, and
inflammation,9-11 but this is the first to specifically study the
effects of hypercholesterolemia and chronic ischemia, 2
conditions that are quite prevalent among the cardiac patient
population, in the setting of celecoxib treatment.
The term ‘‘thrombogenic ratio’’ was first coined by Oubina
and colleagues12 in 2001. Several studies have since found that
high oil intake and serum cholesterol, while increasing sys-
temic levels of both thromboxane andprostacyclin, donot alter
the thrombogenic ratio.12,13 A key finding in this study is that,
in the setting of celecoxib treatment, hypercholesterolemia
significantly increased the thrombogenic ratio in both
ischemic and nonischemic myocardium, suggesting that
hypercholesterolemia may affect prostanoid balance
differently in the setting of celecoxib treatment. Although
the expressions of thromboxane and prostacyclin syntha-
ses were not altered by a high-fat diet, hypercholesterolemia
may shift thromboxane production in the heart to be regu-
lated primarily by COX-1, such that selective inhibition of
COX-2 preferentially inhibits prostacyclin production over
thromboxane production.ery c September 2011
FIGURE 4. Immublotting results. Expression of thromboxane synthase, prostacyclin synthase, myeloperoxidase (MPO), Cu/Zn-superoxide dismutase
(Cu/Zn-SOD),Mn-superoxide dismutase (Mn-SOD), and total protein oxidative stress was measured in myocardial tissue lysates and expressed in arbitrary
units of optical density (OD). Shown are representative lanes from the same set of gels for each graph; images have been truncated for easier visualization.
Expression of thromboxane synthase (A) and prostacyclin synthase (B) was not significantly different between groups, while MPO (C), Cu/ZN-SOD (D),
Mn-SOD (E), and total protein oxidation (F) were all increased in ischemic myocardium compared with nonischemic myocardium. *P<.05, yP<.01,
zP<.001.
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SAlthough we did not specifically examine platelet aggre-
gation in this study, a higher thrombogenic ratio could
predispose to vasoconstriction and clot formation in the cor-
onary vasculature of hypercholesterolemic patients taking
celecoxib, leading to increased cardiovascular risk. Concor-
dantly, we found that myocardial perfusion tended to be de-
creased in hypercholesterolemic animals in this study. The
effect of HDL and LDL on prostanoid balance is quite
controversial. Hypercholesterolemia has been shown to in-
crease urinary excretion of thromboxane metabolites,14 and
statin treatment effectively decreases urinary excretion of
both thromboxane and prostacyclin metabolites,15 but
ours is the first study to specifically examine myocardial
levels of thromboxane and prostacyclin. Yui and associ-
ates16 reported that HDL stabilizes circulating prostacyclin.
It may be that although the HDL/LDL ratio was decreased
in HCX animals, the increase in absolute HDL prolonged
the action of myocardial prostacyclin on the coronary vas-
culature. Furthermore, prostanoid balance fluctuates in re-
sponse to certain diseases that limit blood flow such asThe Journal of Thoracic and Cachronic myocardial ischemia,17 which may account for
the decrease in thrombogenic ratio we saw in ischemic
myocardium in this study. The interaction between cardio-
vascular comorbidities and prostanoid balance is obviously
quite complex and requires further investigation.
Myocardial ischemia, hypercholesterolemia, and arachi-
donic acid metabolism are all associated with the release
of reactive oxygen species.18 When sufficient reactive oxy-
gen species are produced to overcome cellular defense
mechanisms, they can damage or denature proteins, leading
to enzyme deactivation, loss of contractile function, and vas-
cular dysfunction.19 In this study, both total protein oxida-
tive stress and myeloperoxidase, a sensitive marker for
myocardial oxidation and inflammation, were increased in
ischemic myocardium. Interestingly, although hypercholes-
terolemia has been shown in multiple models to increase
oxidative stress, we did not observe this in celecoxib-
treated swine. Celecoxib has been found to increase oxida-
tive stress in healthy animals,20,21 but it actually decreases
oxidative stress in models of malignancy22 and rats exposedrdiovascular Surgery c Volume 142, Number 3 679
FIGURE 5. Vessel density. Capillary density and arteriolar density were measured by immunohistochemical staining for CD31 and smooth muscle actin,
respectively, and expressed as vessels per square millimeter. Therewas no significant difference in capillary or vessel density between any of the groups.CX,
Normal chow; HCX, high cholesterol diet; NV, nonischemic left ventricular tissue; AAR, area at risk.
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Sto reactive oxygen species–rich cigarette smoke.23 Similarly,
celecoxib may have decreased oxidative stress in the proin-
flammatory environment of chronic hypercholesterolemia in
this study. We hypothesized that this antioxidant effect may
have been mediated by increased expression of the free-
radical scavenger SOD, but both Cu/Zn-SOD and Mn-SOD
were not upregulated in the hypercholesterolemic group.
The increasedSODexpression seen in the ischemic territories
is likely a response to the increase in oxidative stress.
Overall, hypercholesterolemia produced minimal differ-
ences in ventricular function and angiogenesis as measured
by vessel density in the present study. This was somewhat
unexpected, inasmuch as previous studies by our group
and others have shown that these parameters are negatively
affected by hypercholesterolemia.24,25 LV contractility was
actually found to be increased in this study, and mean
arterial pressure tended to be decreased in the HCX
group. Recent evidence from our laboratory and others
suggests that a beneficial effect of celecoxib may be
responsible for this phenomenon. We recently reported
that, specifically in hypercholesterolemic swine, celecoxib
actually increases myocardial perfusion and function in
the AAR (Chu et al, submitted to Am J Physiol, 2011),
and others have shown that the drug acts as a peripheral
vasodilator in patients with coronary artery disease.7 With
so many potential clinical applications, celecoxib certainly
warrants further investigation, but this study shows that car-
diovascular comorbidities such as coronary artery disease
and hypercholesterolemia must be taken into account
when assessing the safety of celecoxib moving forward.LIMITATIONS
This study has several potential limitations. First, the re-
sults of this study do not necessarily reflect what would be
found in a clinical trial with thousands of patients. Certain
relatively rare events may occur through nonvascular mech-
anisms that would only become evident in a large clinical680 The Journal of Thoracic and Cardiovascular Surgtrial. Second, COX inhibitors differ in their degree of selec-
tivity for COX-1 and COX-2, so that the results of this study
should not be generalized to other members of the class of
drugs. Finally, inasmuch as the purpose of this study was to
primarily assess the effects of hypercholesterolemia and
chronic ischemia on the cardiovascular environment in the
setting of celecoxib treatment, we did not include non–
drug treated groups in this study. Thus, one should be care-
ful in drawing conclusions about the specific cardiovascular
effects of celecoxib from the data obtained in this study.
We thank the Animal Research Facility of Beth Israel Deacon-
ess Medical Center and the Central Research Facility of Rhode
Island Hospital for their excellent care of the animals used in
this study.References
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Dr Michael E. Jessen (Dallas, Tex). I enjoyed your study, but
several of the observation that you made seemed counterintuitive.The Journal of Thoracic and CaFor example, what is your explanation for why what you call con-
tractility actually was greater in the ischemic zones?
DrChu.That is a very good question.Wewere surprised by that
as well. I think the other surprising thing that we also found was
that mean arterial pressure was actually decreased in the high-cho-
lesterol animals. The improvement in contractility may have some
relationship with the decreased mean arterial pressure and de-
creased afterload, but we are not really sure why that is. It may
be an effect of the drug celecoxib (Celebrex), but without having
a controlled, non–drug-treated group, it would be hard to make
that conclusion.
Dr Jessen. If what you are calling contractility is affected by
afterload, then it is really not contractility by a pure definition.
Did you consider doing anything to measure dimensions in those
2 zones to try to get a better handle on that?
Dr Chu. Unfortunately, we did not; we did not do any echo or
any pressure–volume loop analysis. We are moving into that realm
now, so I hope in future studies we will be able to look at those
things.
Dr Jessen. The other thing was that the contractility was in-
creased, but this was in areas where there was decreased blood
flow. Was that what I took from your talk?
Dr Chu. There was a trend toward decreased blood flow, but it
was not statistically significant.
Dr Jessen. That would be an unusual combination of events as
well. Finally, what is your explanation for the ischemic areas
seeming to have a decreased thrombogenic ratio? That seems
counterintuitive as well.
Dr Chu. That is a great question as well. As you know, throm-
boxane and prostacyclin are partially released by the endothelium
in tissues in the body. It is possible that ischemia affects the
balance of the release of those prostanoids to favor prostacyclin re-
lease, thus decreasing the thrombogenic ratio. Again, the explana-
tion for that is uncertain at this point.
Dr PatrickM.McCarthy (Chicago, Ill). The bottom line ques-
tion is, if your dad was receiving celecoxib and that was the last
available drug that actually works well for his arthritis, how would
you balance these factors?
Dr Chu. Right. That is the million dollar question. However,
this study was not really adequately designed to specifically assess
the safety profile of celecoxib because we did not include a non–
drug-treated group. However, we have done another study that is
currently under review comparing celecoxib use in high-choles-
terol pigs to non–drug-treated high-cholesterol pigs. It does sur-
prise me to have some beneficial effects with regard to reducing
oxidative stress, actually increasing blood flow in the ischemic
territory. I think definitely the safety profile of the drug deserves
further investigation.rdiovascular Surgery c Volume 142, Number 3 681
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